Systemic therapy in non-small-cell lung cancer

被引：0

作者：

Jazieh, Abdul-Rahman ^{[1
]}

Saadeen, Ahmed ^{[2
]}

机构：

[1] King Abdulaziz Med City Natl Guard, Dept Oncol, Riyadh 11426, Saudi Arabia

[2] Riyadh Mil Hosp, Riyadh, Saudi Arabia

来源：

ANNALS OF THORACIC MEDICINE | 2008年 / 3卷 / 06期

关键词：

Lung cancer; systemic therapy; treatment;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The systemic treatment of lung cancer has evolved rapidly over the last two decades. Systemic therapy has become the standard of care for advanced lung cancer up to the third line. The addition of antiangiogenesis agents to chemotherapy has proved to be beneficial in the first-line setting. Finally, systemic therapy has proven effective in the adjuvant setting in early-stage lung cancer.

引用

页码：S97 / S99

页数：3

共 18 条

[1] Concurrent cisplatin, etoposide, and chest radiotherapy in Pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group Phase II Study, SWOG 9019 [J].

Albain, KS ;

Crowley, JJ ;

Turrisi, AT ;

Gandara, DR ;

Farrar, WB ;

Clark, JI ;

Beasley, KR ;

Livingston, RB .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3454-3460

[2]

[Anonymous], 2005, J Clin Oncol

[3] Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol [J].

Belani, CP ;

Choy, H ;

Bonomi, P ;

Scott, C ;

Travis, P ;

Haluschak, J ;

Curran, WJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5883-5891

[4] Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]):: a randomised controlled trial [J].

Douillard, Jean-Yves ;

Rosell, Rafael ;

De Lena, Mario ;

Carpagnano, Francesco ;

Ramlau, Rodryg ;

Gonzales-Larriba, Jose Luis ;

Grodzki, Tornasz ;

Pereira, Jose Rodrigues ;

Le Groumellec, Alain ;

Lorusso, Vito ;

Clary, Claude ;

Torres, Antonio J. ;

Dahabreh, Jabrail ;

Souquet, Pierre-Jean ;

Astudillo, Julio ;

Fournel, Pierre ;

Artal-Cortes, Angel ;

Jassem, Jacek ;

Koubkova, Leona ;

His, Patricia ;

Riggi, Marcella ;

Hurteloup, Patrick .

LANCET ONCOLOGY, 2006, 7 (09) :719-727

[5] Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group [J].

Fossella, F ;

Pereira, JR ;

von Pawel, J ;

Pluzanska, A ;

Gorbounova, V ;

Kaukel, E ;

Mattson, KV ;

Ramlau, R ;

Szczesna, A ;

Fidias, P ;

Millward, M ;

Belani, CP .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3016-3024

[6] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].

Fossella, FV ;

DeVore, R ;

Kerr, RN ;

Crawford, J ;

Natale, RR ;

Dunphy, F ;

Kalman, L ;

Miller, V ;

Lee, JS ;

Moore, M ;

Gandara, D ;

Karp, D ;

Vokes, E ;

Kris, M ;

Kim, Y ;

Gamza, F ;

Hammershaimb, L .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362

[7] Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer [J].

Furuse, K ;

Fukuoka, M ;

Kawahara, M ;

Nishikawa, H ;

Takada, Y ;

Kudoh, S ;

Katagami, N ;

Ariyoshi, Y .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2692-2699

[8] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].

Hanna, N ;

Shepherd, FA ;

Fossella, FV ;

Pereira, JR ;

De Marinis, F ;

von Pawel, J ;

Gatzemeier, U ;

Tsao, TCY ;

Pless, M ;

Muller, T ;

Lim, HL ;

Desch, C ;

Szondy, K ;

Gervais, R ;

Shaharyar ;

Manegold, C ;

Paul, S ;

Paoletti, P ;

Einhorn, L ;

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597

[9] A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung [J].

Kato, H ;

Ichinose, Y ;

Ohta, M ;

Hata, E ;

Tsubota, N ;

Tada, H ;

Watanabe, Y ;

Wada, H ;

Tsuboi, M ;

Hamajima, N ;

Ohta, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (17) :1713-1721

[10] Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer [J].

Le Chevalier, T ;

Arriagada, R ;

Le Péchoux, C ;

Grunenwald, D ;

Dunant, A ;

Pignon, JP ;

Tarayre, M ;

Abratt, R ;

Arriagada, R ;

Bergman, B ;

Gralla, R ;

Grunenwald, D ;

Le Chevalier, T ;

Orlowski, T ;

Papadakis, E ;

Pinel, MIS ;

Araujo, C ;

Della Torre, H ;

de Solchaga, MM ;

Abdi, E ;

Blum, R ;

Ball, D ;

Basser, R ;

De Boer, R ;

Bishop, J ;

Brigham, B ;

Davis, S ;

Fox, D ;

Richardson, G ;

Wyld, D ;

Pirker, R ;

Humblet, Y ;

Delaunois, L ;

Van Meerbeeck, JP ;

Germonpre, P ;

Vansteenkiste, J ;

Nackaerts, K ;

Pinel, MIS ;

Vauthier, G ;

Younes, RN ;

Arriagada, R ;

Baeza, R ;

Carvajal, P ;

Kleinman, S ;

Orlandi, L ;

Castro, C ;

Godoy, J ;

Kosatova, K ;

Gaafar, R ;

Azarian, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (04) :351-360

← 1 2 →